News & Updates

The combination of olaparib and abiraterone in the first-line setting improved radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), results of the phase III PROpel trial showed.

Treatment with roxadustat leads to significant improvements in renal anaemia among patients with chronic kidney disease (CKD) by increasing haemoglobin (Hb) level and iron metabolism, according to a recent study. However, the risk of serious adverse events (AEs) during treatment must be considered.

Children with bacterial meningitis appear to fare well with corticosteroids, which lead to a lower incidence of hearing loss and neurologic sequelae and faster resolution of fever, according to a meta-analysis.

Use of sofosbuvir-based direct-acting antiviral regimens for treating hepatitis C virus (HCV) in clinical trial participants with chronic kidney disease (CKD) does not appear to worsen estimated glomerular filtration rate levels, according to a study. Furthermore, the drug does not appear to contribute to an increased risk of end-stage renal disease among HCV patients with CKD treated in clinical practice.

Polypharmacy (PP) arises in nearly one in five patients with inflammatory bowel disease (IBD), particularly in older adults and those with comorbidity, according to a study, adding that PP can complicate adherence to treatment and therapeutic success.

In men with erectile dysfunction (ED), adjuvant daily oral therapy with L-arginine and tadalafil was effective and safe in enhancing the efficacy and duration of benefits of low-intensity extracorporeal shockwave therapy (Li-ESWT), a study has shown.